DOCSLIB.ORG

Emmett Cunningham, Jr., M.D., Ph.D., M.P.H

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2019 - Emmett Cunningham, Jr., M.D., Ph.D., M.P.H. Senior Managing Director Blackstone Life Sciences HEATHEGY TEAM CRAIG SIMAK CRAIG SIMAK DANIELLE SILVA MAUREEN LINNEMANN 1200 OIS@AAO 24 Meetings > 1,150 1000 ~ 13,500 Attendees 800 OIS@ASCRS 600 > 650 400 OIS@ASRS 200 > 300 0 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Registrants 3% 10% OIS@AAO 2019 ( > 1,150) 8% Academia, Government, or Association 41% Adviser, Consultant, or Service Provider Finance/Investment Firm Large Multi-National Corporation Physician/Healthcare Provider 25% Press/Media Start-up/Emerging Growth Company 3% 25 Countries 10% 32 US States Record Number of CDER NME NDA/BLA Approvals in 2018 70 BLA 59 60 NDA 50 45 46 Number 39 41 of 40 35 36 Drugs 30 30 30 27 27 24 26 22 24 21 20 21 22 20 17 18 10 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Source: FDA 1998 - 2018 High Innovation Record Number of • 31 (53%) Orphan CDER NME NDA/BLA Approvals in 2018 • 26 (44%) Priority Review • 16 (27%) Fast Track • 12 (20%) Break Through Designation 59 • 18 (30%) Oncology • 1 (0%) Ophthalmology Cenegermin-bkbj Ophthalmic Solution, (OXERVATE®) Ophthalmic Drugs Streamlined Reporting of Ophthalmology Clinical Group CDER As of January, 2018 Ophthalmology Clinical Group Reported Directly & Independently to Deputy Director Office of New Drugs Peter Stein, MD Five Additional Office of Offices of Drug Antimicrobial Evaluation (ODEs) Products Division of Division of Division of Transplant and Anti-Infective Anti-Viral Ophthalmology Products Products Dr. Wiley A. Chambers Products Supervisory Medical Officer Division of Transplant and Ophthalmology Products (DTOP) Re-Org Officially Approved September 26, 2019 https://www.fda.gov/drugs/regulatory-science-research-and-education/reorganization-office-new-drugs-corresponding-changes-office-translational-sciences-and-office Original NDA/BLA Approvals – 1988 to 2019 Center for Drug Evaluation and Research 2019 160 129 140 120 100 80 60 • Range: 0 – 9 • Mean: 4.4 40 Ophthalmic / Year • Median: 4 20 7 0 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Ophthalmic Approvals Total Approvals Linear (Ophthalmic Approvals) Linear (Total Approvals) Data provided by : Wiley A. Chambers, MD Gary Novack, PhD Supervisory Medical Officer Pharma . Logic Consulting, Inc. Division of Transplant and Ophthalmology Products Original NDA/BLA Approvals Center for Drug Evaluation and Research - FY2019 140 7 5.4% Ophthalmic 122 October 1, 2018 thru September 30, 2019 120 • Fluocinolonide acetonide intravitreal implant (YUTIQ®), 0.18mg, a corticosteroid implant indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, October 12, 2018 (NDA) – Eyepoint 100 Pharmaceuticals, Inc. •Dexamethasone Ophthalmic Insert (DEXTENZA®), 0.4mg, a corticosteroid insert indicated for the treatment of ocular pain associated with ophthalmic surgery. November 30, 2018 (NDA) – Ocular Therapeutix, Inc. 80 •Loteprednol etabonate ophthalmic gel (LOTEMAX SM®), 0.38% in new formulation to treat post-operative inflammation and pain following ocular surgery, February 22, 2019 (NDA) – Bausch & Lomb, Inc. • Tetracaine hydrochloride ophthalmic solution, 0.5% , local ophthalmic anesthetic – March 12, 2019 (NDA) – 60 Bausch & Lomb, Inc. • Netarsudil / Latanoprost (ROCKLATAN®), 0.02%/0.005%, fixed dose combination for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, March 12, 2019 (NDA) – Aerie 40 Pharmaceuticals, Inc. • Acyclovir Ophthalmic Ointment (AVACLYR®), 3.0%, indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus, March 29, 2019 (NDA) – Fera Pharmaceuticals, LLC. 20 •Brolucizumab (Beovu®), 6mg/0.05mg, indicated for the treatment of wet age-related macular degeneration, October 8, 2019, Novartis AG 0 Ophthalmic Non-Ophthalmic Data provided by : Wiley A. Chambers, MD Gary Novack, PhD Supervisory Medical Officer Pharma . Logic Consulting, Inc. Division of Transplant and Ophthalmology Products FDA Approved October 12, 2018 YUTIQTM SHAM Fluocinolone acetonide intravitreal implant, 0.18 mg (YUTIQ™), contains a corticosteroid and is indicated for the Fluocinolone Acetonide treatment of chronic non-infectious uveitis affecting the Intravitreal Implant posterior segment of the eye. FDA Approved November 30, 2018 First FDA Approved Punctal Plug Delivery System Dexamethasone Ophthalmic Insert (DEXTENZA®), 0.4mg A corticosteroid insert indicated for the treatment of ocular pain associated with ophthalmic surgery. November 30, 2018 (NDA) FDA Approved February 22, 2019 Proportion of Patients with Complete Resolution of ACC at Day 8 (Pooled Analysis) 60% LOTEMAX® SM (n=371) P<0. 40% 0001 30% 20% 15% 0% Day 8 Loteprednol etabonate ophthalmic gel (LOTEMAX SM®), 0.38% in new formulation to treat post-operative inflammation and pain following ocular surgery FDA Approved - March 12, 2019 Launched – May, 2019 First Fixed-Dose Combination Containing a PGA First Once-Daily Fixed-Dose Combination Netarsudil / Latanoprost (ROCKLATAN®), 0.02%/0.005%, is a fixed-dose combination indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension “Beovu® is the first to offer less frequent dosing in the first year of therapy while maintaining its effectiveness.” October 8, 2019 Brolucizumab (Beovu®), 6mg/0.05mg “More than half of patients on brolucizumab (56% indicated for the treatment of wet in HAWK, 51% in HARRIER) age-related macular degeneration were able to maintain a 3-month dosing interval” Number of CDER NME NDA/BLA Approvals, 2015-2019* 59 60 All Indications 60 Ophthalmology 50 50 45 46 40 40 30 30 30 22 20 20 10 10 3 0 1 1 1 0 0 2015 2016 2017 2018 2019* 2015 2016 2017 2018 2019* * 2019 Through October 8, 2019; FDA Global Ophthalmic Pharmaceutical Market Revenues by Specialty 50 Total ($B) 42.14 40 6.9 Total ($B) 29.04 6.5 30 6.2 6.3 20 4.9 Revenues ($B) Revenues 4.9 Anti-VEGF 10 22.4 13.0 Largest 0 2019 2024 IVT Anti-VEGF (AMD, DME, RVO, Etc.) Glaucoma Pharmaceuticals Dry Eye All Other Source: Market Scope Estimates 2019; Courtesy Market Scope. http://market-scope.com/ Market Scope ® IVT Injections…. Courtesy Dr. Peter Karth and Dr. Marc Blumenkranz Global Anti-VEGF Injections (M) Global 25 24.4M 20 Ex-US 17.5M 15 10 IVT Injections Injections IVT (M) US 5 6.9M 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 United States Outside United States Global Source: Market Scope Estimates 2019; Courtesy Market Scope. http://market-scope.com/ Market Scope ® Wet AMD OPT-302-1002 – Mean Change in VA Over Time Additive benefit of OPT-302 evident from 8-weeks Mean Gains in Visual Acuity From Baseline Benefit of Pan-VEGF Inhibition (A + C + D) +14.2 *p = 0.0107 +10.8 +9.4 Sham + Lucentis® (0.5 mg) OPT-302 (0.5 mg) + Lucentis® (0.5 mg) OPT-302 (2.0 mg) + Lucentis® (0.5 mg) (n = 119) (n = 122) (n = 121) OPT-302-1002 clinical trial (NCT03345082). Graph represents observed data and standard error of the mean (SEM). Modified Intent-to-treat study population. BCVA, Best Corrected Visual Acuity; ETDRS, Early Treatment Diabetic Retinopathy Study. * Difference in Least Square Means, using Model for Repeated Measures (MRM) analysis. Control of Type I error via the Hochberg Procedure. GB-102 – Small Molecule TKI (Sunitinib – Pan VEGFR Antagonist) • Best performing dose • ~90% of patients rescue-free at 6 Months • ~60% of patients rescue-free at 8 months • Excellent safety profile • Phase 2a in Macular Edema Q3 2019 • Phase 2b in wAMD Q3 2019 Antibody Biopolymer Conjugates (ABCs): a new scientific design platform for extended durability intravitreal therapeutics • Phase 1 Data: 110+ Patients: wAMD, DME (NPDR, PDR), RVO • Safety: 300+ injections: no inflammation or other safety signals • Efficacy: strong anti-VEGF efficacy in each indication • Durability: wAMD dosing interval of 3-5 months in emerging data (Retina Society) KSI-301: anti- VEGF ABC Antibody and optically clear, branched, high molecular weight phosphorylcholine biopolymer covalently bound via single, site- specific stable linkage • New durability data in wAMD, DME, and RVO to be presented Friday 10/11 at AAO • Pivotal ‘DAZZLE’ wAMD study: KSI-301 q3-5 month vs Eylea q2mo now enrolling OPTIC Cohort 1 24-week conclusions ADVM-022 AAV.7m8 capsid • Zero rescue injections required • Consistent and sustained anatomical improvements on OCT ITR C11 aflibercept ITR Aflibercept expression cassette • BCVA stability maintained RN • ADVM-022 - safe and well tolerated A Aflibercept Day -14 to -7: Day 1: 24-week safety and 52-week safety and aflibercept ADVM-022 efficacy assessment efficacy assessment Baseline assessment Treatment evaluation Treatment evaluation Follow-up Weeks: 4 8 12 16 20 24 52 104 Rescue at any time if disease activity meets retreatment criteria† Sub – Retinal Delivery REGENXBIO ANNOUNCES EXCLUSIVE WORLDWIDE OPTION AND LICENSE AGREEMENT WITH CLEARSIDE BIOMEDICAL FOR EVALUATION OF IN- OFFICE DELIVERY PLATFORM FOR RGX-314 Ophthalmic Devices 510(k) Clearances Division of Ophthalmic and Ear, Nose and Throat Devices - FY2018 3000 2.2% of Total 2500 2348 54 2000 1500 1000 Ophthalmic 500 Non-Ophthalmic 0 Lee Kramm, MD, MSE & Judy Gordon, DVM ClinReg Consulting Services, Inc. PMA Approvals – 2004 to 2019 Division of Ophthalmic and Ear, Nose and Throat Devices 80 2019 70 60 50 49 40 30 20 10 3 0 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Opthalmic PMA Total PMA Lee Kramm, MD, MSE & Judy Gordon, DVM ClinReg Consulting Services, Inc. PMA Approvals Division of Ophthalmic and Ear, Nose and Throat Devices- FY2018 60 5.8% of Total 3 50 49 40 October 1, 2018 thru September 30, 2019 • Visumax Femtosecond Laser, Carl Zeiss Meditec, Inc.
Recommended publications
  • Symbols Alexian Brothers Health System Index to Nov P

    Symbols Alexian Brothers Health System Index to Nov P

    Volume 19, Index December 2014 Symbols Alexian Brothers Health System Index to Nov p. 2 Health Care M&A News 1-800-CONTACTS Feb p. 18 A&L Goodbody Apr p. 16, July p. 16 All Care Home Health, LLC Feb p. 17 Each company and orga- A Allergan Inc. Feb p. 10, May p. 1, nization discussed in Health May p. 19, Jun p. 15, July p. 3, Care M&A News, from Janu- Abbott Labs July p. 3, Aug p. 17, July p. 10, Sept p. 16, Oct p. 3, ary through December 2014, Dec p. 4 Nov p. 1, Dec p. 4, Dec p. 16, is listed alphabetically here. AbbVie Inc. July p. 3, July p. 16, Dec p. 19 References are typically to Aug p. 9, Oct p. 2, Oct p. 16, Allscripts Feb p. 2, Apr p. 10 the first occurrence of the Nov p. 19, Dec p. 2 AllSpire Health Partners Nov p. 2 company’s or organiza- ABL, Inc. Aug p. 18 All Staffing Services Jan p. 17 tion’s name in the pertinent Acadia Healthcare Company Feb p. 16, Almost Family, Inc. Apr p. 16 issue; further discussion July p. 17, Oct p. 17, Nov p. 17 ALN Medical Management, LLC may follow later in the text Accelera Innovations, Inc. Jan p. 17 Accelrys, Inc. Jan p. 15 Feb p. 8 but is not indicated here. AccessClosure, Inc. May p. 15 Alta Partners Jun p. 16 Achillion Pharmaceuticals July p. 17 Altos Solutions, Inc. Jun p. 15 References are sorted by Actavis (Foshan) Pharmaceuticals Co.
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0152273 A1 Merchant Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2017/0152273 A1 Merchant Et Al

    US 20170152273A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0152273 A1 Merchant et al. (43) Pub. Date: Jun. 1, 2017 (54) TOPCAL PHARMACEUTICAL Publication Classification FORMULATIONS FOR TREATING (51) Int. Cl. NFLAMMLATORY-RELATED CONDITIONS C07F 5/02 (2006.01) Applicant: A6II 47/06 (2006.01) (71) Anacor Pharmaceuticals Inc., New A69/06 (2006.01) York, NY (US) A6IR 9/00 (2006.01) (72) Inventors: Tejal Merchant, Cupertino, CA (US); A6II 47/8 (2006.01) Dina Jean Coronado, Danville, CA A6II 45/06 (2006.01) (US); Charles Edward Lee, Union A6II 47/10 (2006.01) City, CA (US); Delphine Caroline A6II 3/69 (2006.01) Imbert, Cupertino, CA (US); Sylvia (52) U.S. Cl. Zarela Yep, Milpitas, CA (US) CPC .............. C07F 5/025 (2013.01); A61K 47/10 (2013.01); A61K 47/06 (2013.01); A61K3I/69 (73) Assignee: Anacor Pharmaceuticals Inc., New (2013.01); A61K 9/0014 (2013.01); A61 K York, NY (US) 47/183 (2013.01); A61K 45/06 (2013.01); A61K 9/06 (2013.01); C07B 2.200/13 (21) Appl. No.: 15/364,347 (2013.01) (22) Filed: Nov. 30, 2016 (57) ABSTRACT Related U.S. Application Data (60) Provisional application No. 62/420,987, filed on Nov. Topical pharmaceutical formulations, and methods of treat 11, 2016, provisional application No. 62/260,716. ing inflammatory conditions with these formulations, are filed on Nov. 30, 2015. disclosed. Patent Application Publication Jun. 1, 2017. Sheet 1 of 4 US 2017/0152273 A1 ?zzzzzzzzzzzzzzzzzzzzzzzzzzzz ????????????????????????????????????????????????????????????????????? S&S&S Šx&N Sssssssssssssssssssssssssssssssssssssss (r) eqn. O. peppy jeeNA go eunO/A Patent Application Publication Jun.
  • Infectious Diseases

    Infectious Diseases

    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
  • Preclinical Development & IND Filing: Nuts, Bolts, Best Practices

    Preclinical Development & IND Filing: Nuts, Bolts, Best Practices

    “Preclinical Development & IND Filing: Nuts, Bolts, Best Practices and Regulatory Aspects.” Speakers: Amit Kalgutkar (Pfizer), Chandra Prakash (Agios), Sanjeev Thohan (Novartis), Li- Chun Wang (Takeda), Wei Yin (Biogen) Organizers: Sanjeev Thohan and Chandra Prakash Date: 6/29/2017 Time: 8:30 am – 5.00 pm Location: Boston/Cambridge Area: Marriott Kendall Square, 50 Broadway, Cambridge MA 02142 Fees: $175 - Regular (before June 1st, 2017), $225 - Regular (after June 1st, 2017); $125 - Unemployed & Academic; $2000 - Major Sponsorship; $475 - Vendor Show Registration: www.PBSS.org Workshop Description: An investigational new drug application (IND) is an important milestone that marks the entry of a molecule into clinical development. Knowing the objectives, expectations and processes of assembling an IND is a key to not only successful filing, but also a promising clinical development path forward. Often there are cases where too many of our “nice-to-have” studies crowd the package at the expense of critical study needs/issues. This can lead to significant delays in clinical developments with back-and-forth of Q&A sessions both internally and with regulatory agencies. As we have seen, the regulatory landscape is changing as rapidly as the industry innovates into new therapeutic modalities. Therefore, it is critical to keep up to date on regulatory requirements and the industry’s best practices in different aspects of the IND: non- clinical safety, PK, CMC, and clinical plans. In this workshop, our speakers who bring years of experience with multiple successful IND filings, will discuss systematically the preclinical studies required for small molecule IND’s as well as the nuts and bolts of putting together a high–quality IND package.
  • Updated: May 20, 2021 Prior Authorization Drugs (NEW ADDITIONS HIGHLIGHTED)

    Updated: May 20, 2021 Prior Authorization Drugs (NEW ADDITIONS HIGHLIGHTED)

    Updated: May 20, 2021 Prior Authorization Drugs (NEW ADDITIONS HIGHLIGHTED) A Abatacept (ORENCIA) Abemaciclib (VERZENIO) Abiraterone Acetate (ZYTIGA) Abiraterone Acetate (+ GENERIC FORMULATIONS) AbobotulinumtoxinA (DYSPORT) Abraxane (ABRAXANE) Acalabrutinib (CALQUENCE) Actemra (ACTEMRA) Adalimumab (AMGEVITA) Adalimumab (HADLIMA) Adalimumab (HULIO) Adalimumab (HUMIRA) Adalimumab (HYRIMOZ) Adalimumab (IDACIO) Adcetris (ADCETRIS) Adcirca (ADCIRCA) Adempas (ADEMPAS) Afatinib (GIOTRIF) Afinitor (AFINITOR) Aflibercept (EYLEA) Aflibercept (ZALTRAP) Afstyla (AFSTYLA) Agalsidase Alfa (REPLAGAL) Agalsidase Beta (FABRAZYM) Aimovig (AIMOVIG) Ajovy (FREMANEZUMAB) Aldesleukin (PROLEUKIN) Aldurazyme (ALDURAZYME) Alecensaro (ALECENSARO) Alectinib (ALECENSARO) Alefacept (AMEVIVE) Alemtuzumab (MABCAMPATH) Alemtuzumab (LEMTRADA) Alglucosidase Alfa (MYOZYME) Alimta (ALIMTA) Alirocumab (PRALUENT) Alpha-1-Proteinase Inhibitor (PROLASTIN - C) Alpha-1-Proteinase Inhibitor (ZEMAIRA) Alpelisib (PIQRAY) Alunbrig (ALUNBRIG) Ambrisentan (VOLIBRIS) Ambrisentan (Generic Formulations) Amevive (AMEVIVE) Amgevita (ADALIMUMAB) Amifampridine Phosphate (FIRDAPSE) Amifampridine Phosphate (RUZURGI) Anakinra (KINERET) Apalutamide (ERLEADA) Apomorphine (KYNMOBI) Apremilast (OTEZLA) Page 1 of 17 Updated: May 20, 2021 Arsenic Trioxide (TRISENOX) Arsenic Trioxide (Generic Formulations) Arzerra (ARZERRA) Asfotase Alfa (STRENSIQ) Asparaginase (ERWINASE) Asunaprevir (SUNVEPRA) Atezolizumab (TECENTRIQ) Atriance (ATRIANCE) Aubagio (AUBAGIO) Avastin (AVASTIN) Avelumab (BAVENCIO) Avonex
  • 761094Orig1s000

    761094Orig1s000

    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761094Orig1s000 CLINICAL REVIEW(S) Medical Officer’s Review of BLA 761094 Review #2 BLA 761094 Submission Date: July 19, 2018 Receipt Date: July 19, 2018 Review Date: July 23, 2018 Applicant: Dompé farmaceutici S.p.A. Via Santa Lucia 6-20122 Milan, Italy Applicant’s Representative: Lamberto Dionigi. Regulatory Affairs & Drug Safety Director 39-02-5838-3559 Drug: OXERVATE (cenegermin – bkbj) ophthalmic solution, 20 mcg/mL Submitted: Reference is made to the meeting Teleconference of 15-July-2018, in which the FDA has requested to provide information available at Dompé on the use of Oxervate in the pediatric population. Pediatric patients exposed to Oxervate: Dompé confirms that Oxervate is not yet approved in Europe for use in children and no clinical studies have been conducted in this population. As far as the company is aware, four (4) Neurotrophic Keratitis (NK) pediatric patients, aged from 2 to 12 years of age, have been exposed to Oxervate. A 6-year-old child with severe NK secondary to Stuve-Wiedmann syndrome was treated with Oxervate under “Temporary Authorization for Use” (ATU) in France. Dompé reports that the corneal ulcer was completely healed at the end of the treatment. There were signs of corneal sensitivity recovery by month 8 post-treatment. A 9-year-old child with NK was treated with Oxervate under ATU in France. Dompé reports that the lesion improved, but did not completely heal with the treatment. There is no other follow-up information available. A 12-year-old child with severe NK was treated with Oxervate under Expanded Access in the US.
  • Healthcare & Life Sciences Group

    Healthcare & Life Sciences Group

    HEALTHCARE & LIFE SCIENCES GROUP 2 1 Healthcare and life sciences clients have long turned to S&C for help succeeding in today’s rapidly changing business environment. Large and mid-size, public and private, throughout their lifecycles, these companies rely on our multi-disciplinary, global team to address their most complex legal and business challenges and reach their strategic goals. Sector expertise: We offer unrivaled OUR CLIENTS GET… knowledge of the healthcare and life sciences industries, our clients’ businesses and the sector-specific competitive pressures bearing down on them. Sullivan & Cromwell’s Healthcare and Life Sciences Group has negotiated complex transactions and resolved high-stakes disputes for almost three decades. Today, it possesses an unparalleled grasp of these sectors and a practical understanding of the commercial realities underlying them. We position our clients to succeed through it all. The Firm represents international clients in the following healthcare sectors: Pharmaceuticals and Life Sciences Medtech Health Insurers Healthcare Services 2 Legal expertise: Clients come to us An integrated, global team: for the high-quality counsel and hands-on We’re a core group of dedicated healthcare representation we offer across multiple advisers across our 13 offices on four legal specialties, to successfully execute continents with a strong track record of their most important deals and resolve the sector’s most significant transactions critical disputes. We can execute any type and litigation matters, supported by all of transaction in any economic climate or the resources of an integrated, global firm. geographic region. Our experience in this We’re grateful to our clients for trusting sector includes: us with their future, and we’ll continue to help them position themselves for growth M&A and success in this exciting and ever- Corporate finance changing industry.
  • NASDAQ Stock Market

    NASDAQ Stock Market

    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
  • W W W .Bio Visio N .Co M New Products Added in 2020

    W W W .Bio Visio N .Co M New Products Added in 2020

    New products added in 2020 Please find below a list of all the products added to our portfolio in the year 2020. Assay Kits Product Name Cat. No. Size Product Name Cat. No. Size N-Acetylcysteine Assay Kit (F) K2044 100 assays Human GAPDH Activity Assay Kit II K2047 100 assays Adeno-Associated Virus qPCR Quantification Kit K1473 100 Rxns Human GAPDH Inhibitor Screening Kit (C) K2043 100 assays 20 Preps, Adenovirus Purification Kit K1459 Hydroxyurea Colorimetric Assay Kit K2046 100 assays 100 Preps Iodide Colorimetric Assay Kit K2037 100 assays Aldehyde Dehydrogenase 2 Inhibitor Screening Kit (F) K2011 100 assays Laccase Activity Assay Kit (C) K2038 100 assays Aldehyde Dehydrogenase 3A1 Inhibitor Screening Kit (F) K2060 100 assays 20 Preps, Lentivirus and Retrovirus Purification Kit K1458 Alkaline Phosphatase Staining Kit K2035 50 assays 100 Preps Alpha-Mannosidase Activity Assay Kit (F) K2041 100 assays Instant Lentivirus Detection Card K1470 10 tests, 20 tests Beta-Mannosidase Activity Assay Kit (F) K2045 100 assays Lentivirus qPCR Quantification Kit K1471 100 Rxns 50 Preps, Buccal Swab DNA Purification Kit K1466 Maleimide Activated KLH-Peptide Conjugation Kit K2039 5 columns 250 Preps Methionine Adenosyltransferase Activity Assay Kit (C) K2033 100 assays CD38 Activity Assay Kit (F) K2042 100 assays miRNA Extraction Kit K1456 50 Preps EZCell™ CFDA SE Cell Tracer Kit K2057 200 assays MMP-13 Inhibitor Screening Kit (F) K2067 100 assays Choline Oxidase Activity Assay Kit (F) K2052 100 assays Mycoplasma PCR Detection Kit K1476 100 Rxns Coronavirus
  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
  • Review Article Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives

    Review Article Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Publishing Corporation Dermatology Research and Practice Volume 2012, Article ID 923134, 6 pages doi:10.1155/2012/923134 Review Article Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives Y. Valdman-Grinshpoun,1, 2 D. Ben-Amitai,1, 3 and A. Zvulunov1, 4 1 Pediatric Dermatology Unit, Schneider Children’s Medical Center of Israel, 49202 Petach Tikva, Israel 2 Department of Dermatology, Szold Health Center, Clalit Health Services, 84894 Beer-Sheva, Israel 3 Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel 4 Medical School for International Health, Faculty of Medicine, Ben-Gurion University of the Negev, 84105 Beer-Sheva, Israel Correspondence should be addressed to Y. Valdman-Grinshpoun, [email protected] Received 21 April 2012; Accepted 18 June 2012 Academic Editor: Georgios Stamatas Copyright © 2012 Y. Valdman-Grinshpoun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Atopic dermatitis is a multifactorial, chronic relapsing, inflammatory disease, characterized by xerosis, eczematous lesions, and pruritus. The latter usually leads to an “itch-scratch” cycle that may compromise the epidermal barrier. Skin barrier abnormalities in atopic dermatitis may result from mutations in the gene encoding for filaggrin, which plays an important role in the formation of cornified cytosol. Barrier abnormalities render the skin more permeable to irritants, allergens, and microorganisms. Treatment of atopic dermatitis must be directed to control the itching, suppress the inflammation, and restore the skin barrier.
  • Stamford Therapeutics Consortium Consortiapedia.Fastercures.Org

    Stamford Therapeutics Consortium Consortiapedia.Fastercures.Org

    Stamford Therapeutics Consortium consortiapedia.fastercures.org Stamford Therapeutics Consortium consortiapedia.fastercures.org/consortia/stamford-therapeutics-consortium/ Research Areas At a Glance Status: Active Consortium Tool Development Year Launched: 1994 Clinical Trial Initiating Organization: Dr. Paul Dalgin Data-Sharing Enabler Initiator Type: Industry Location: North America DevelopmentProduct Drugs Abstract Stamford Therapeutics Consortium (STC) is a privately owned and operated clinical research site specializing in phase II, III, and IV clinical trials for the pharmaceutical and biotechnology industries. STC has a strong working relationship with a cardiology group, a large multispecialty medical practice, and a team of physicians who serve as sub-investigators for many of its clinical trials. STC maintains a significant presence in research for the treatment of osteoarthritis and rheumatoid arthritis, while continuing to expand its research into new therapeutic areas. Year after year STC's list of specialties grows to accommodate a growing demand and new innovations in healthcare. With over 15 years of clinical trials operations, STC has conducted more than 350 national and multi-national clinical trials. Mission The company’s sole mission is to conduct the highest quality clinical trials so that new, safe, and effective medications can be developed, researched, and approved for a variety of indications and diseases. Stamford Therapeutics Consortium - consortiapedia.fastercures.org Page 1/4 Stamford Therapeutics Consortium consortiapedia.fastercures.org Consortium History The site was launched in 1994 and has contributed to clinical trials research ever since. Structure & Governance The consortium is governed by their president, medical director, founder, and clinical research coordinators. Patent Engagement STC actively recruits patients from all over Fairfield County, CT and Westchester County, NY.